tiprankstipranks
Advertisement
Advertisement
Mineralys prices offering of 5.66M shares of common stock at $26.50
PremiumThe FlyMineralys prices offering of 5.66M shares of common stock at $26.50
19d ago
Mineralys Secures Lorundrostat Rights and Major Financing Facility
Premium
Company Announcements
Mineralys Secures Lorundrostat Rights and Major Financing Facility
19d ago
Mineralys to repurchase future royalty payments in Tanabe license agreement
Premium
The Fly
Mineralys to repurchase future royalty payments in Tanabe license agreement
19d ago
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
PremiumThe FlyJefferies says Baxfendy approval may be incrementally constructive for Mineralys
1M ago
Mineralys Therapeutics Maps Path After Lorundrostat NDA
Premium
Company Announcements
Mineralys Therapeutics Maps Path After Lorundrostat NDA
2M ago
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
Premium
The Fly
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
2M ago
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
PremiumRatingsMineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
3M ago
Mineralys Therapeutics Charts Path After NDA Acceptance
Premium
Company Announcements
Mineralys Therapeutics Charts Path After NDA Acceptance
3M ago
Mineralys Therapeutics price target raised to $51 from $46 at BofA
Premium
The Fly
Mineralys Therapeutics price target raised to $51 from $46 at BofA
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100